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In a primate model of postnatal virus transmission, we have previously shown that 1 h post-exposure prophylaxis (PEP) with a triple
combination of neutralizing monoclonal antibodies (nmAbs) conferred sterilizing protection to neonatal macaques against oral challenge with
pathogenic simian–human immunodeficiency virus (SHIV). Here, we show that nmAbs can also partially protect SHIV-exposed newborn
macaques against infection or disease, when given as 12 or 24 h PEP, respectively.
This work delineates the potential and the limits of passive immunoprophylaxis with nmAbs. Even though 24 h PEP with nmAbs did not
provide sterilizing immunity to neonatal monkeys, it contained viremia and protected infants from acute disease. Taken together with our results
from other PEP studies, these data show that the success of passive immunization depends on the nmAb potency/dose and the time window
between virus exposure and start of immunotherapy.
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Passive immunoprophylaxis is a very useful tool to inves-
tigate the role of antibodies against HIV infection and, as such,
can be used in primate models of simian–human immunode-
ficiency virus (SHIV) infection, as the latter viruses encode⁎ Corresponding author. Dana-Farber Cancer Institute, 44 Binney Street,
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doi:10.1016/j.virol.2006.07.056HIV-1 env genes in the context of the simian immunodeficiency
virus (SIV) backbone. Because the use of anti-HIV IgG in
preclinical studies in primates led to inconsistent results
(reviewed in Ferrantelli and Ruprecht, 2002), we limited our
studies to combinations of human neutralizing monoclonal
antibodies (nmAbs) known to target conserved envelope
epitopes. Several such anti-HIV nmAbs are currently available,
which are known to neutralize primary HIV isolates of different
clades and groups in vitro (Binley et al., 2004; Ferrantelli et al.,
2004a; Kitabwalla et al., 2003; Stiegler et al., 2001; Trkola et
70 F. Ferrantelli et al. / Virology 358 (2007) 69–78al., 1995; Verrier et al., 2001; Xu et al., 2001; Zwick et al.,
2001a, 2001b), either when used singly or in combinations. We
and others have shown previously (Baba et al., 2000; Ferrantelli
et al., 2003, 2004b; Hofmann-Lehmann et al., 2001, 2002;
Mascola et al., 1999, 2000; Parren et al., 2001; Veazey et al.,
2003) that passive administration with anti-HIVenvelope (Env)
nmAbs can protect monkeys against intravenous (I.V.) or
mucosal challenge with SHIVs.
In our past studies in newborn macaques, we achieved
complete protection against oral challenge with the pathogenic
SHIV89.6P either with a triple or a quadruple combination of
nmAbs administered as 1 h post-virus exposure prophylaxis
(PEP) (Ferrantelli et al., 2004b). Here, we present two
comparative studies that tested the efficacy of PEP with
nmAbs given at 1 h, 12 h or 24 h after virus challenge in
order to define the time window of opportunity for effective
antibody treatment against SHIV infection.
Results
Intravenous PEP with four anti-HIV nmAbs against
SHIV89.6P oral challenge in rhesus newborns
Eleven newborn macaques were challenged orally with the
highly pathogenic SHIV89.6P. Whereas a group of four control
animals was left untreated (Fig. 1A), two treatment groups of
four and three neonatal macaques were treated intravenously
with the combination of IgG1b12, 2G12, 2F5, and 4E10 either
1 h, or 12 h post-virus exposure, respectively; a second
treatment-dose was administered 8 days later (Figs. 1B, C). All
controls displayed high plasma viremia levels (Fig. 1D) and had
steep CD4+ T-cell losses within 14 days (Fig. 1G); all four
rhesus infants were euthanized within 7 weeks of challenge
because of AIDS. In contrast, all treated animals were protected
from either SHIV89.6P infection (Figs. 1E, F) or virus-induced
acute disease (Figs. 1H, I).
Three of the four rhesus newborns that were given 1 h PEP
were protected from persistent systemic infection, with two
animals having undetectable plasma viremia throughout a 47-
month follow-up and one animal, monkey RWq-8, showing a
single very low viremia blip at week 20 post-challenge (not
followed by seroconversion) and again low plasma viremia
between weeks 199 and 206 (Fig. 1E). The fourth nmAb-treated
animal (RYq-8) presented with a delayed-peak plasma viremia
that was almost 100-fold lower than that of the controls; this
animal was protected from CD4+ T-cell depletion (Fig. 1H).
Three of the monkey infants that were treated 1 h post-virus
exposure remained healthy during a 47-month follow-up (Fig.
1H); RAq-8 remained virus negative until it was euthanized at
week 7 of age due to Staphylococcus aureus aspiration
pneumonia unrelated to the virus challenge or nmAb treatment
(Fig. 1H).
Persistent systemic infection was prevented in one out of
three neonatal macaques in the 12 h PEP group (animal RQs-8);
this animal only displayed two blips of transient, low plasma
viral RNA (vRNA) at weeks 16 and 97 post-challenge (Fig. 1F
and data not shown). The other two animals had approximately100-fold lower levels of plasma vRNA than the controls (Fig.
1F); both of these infants were protected from SHIV89.6P-
induced acute disease (Fig. 1I). The macaque with transient
vRNA blips (RQs-8) and RPs-8 were also protected from
disease over a follow-up of nearly 4 years (Fig. 1I), whereas
RYr-8 had severely depleted CD4+ T cells from week 20
following viral exposure onward (Fig. 1I) and was euthanized at
week 69.
Cocultivation experiments of peripheral blood mononuclear
cells (PBMC) of all four monkeys that were protected from per-
sistent systemic infection, RAq-8, RQp-8, RWq-8, and RQs-8,
were virus-negative (not shown). PBMCDNA isolated from the
same animals was also negative by PCR for viral sequences.
Virus status of lymph nodes of protected animals
To determine whether treated animals that displayed
undetectable plasma viremia throughout the study might be
nonetheless latently infected, we tested for the presence of viral
sequences in lymph nodes (LNs). Inguinal LN biopsies were
obtained from SHIV-seronegative animals RQp-8, RWq-8, and
RQs-8 (it was not possible to obtain LNs from RAq-8 because
the animal was no longer in the study at the time biopsies were
performed). LN cells from these animals were negative for both
viral DNA and RNA sequences, except for RWq-8, which
resulted in low positivity for vRNA but not DNA (not shown).
This result is compatible with the fact that RWq-8 was exposed
to the virus and had occasional blips of low-level plasma vRNA
(Fig. 1E).
Intramuscular PEP with three anti-HIV Env nmAbs against
SHIV89.6P oral challenge in neonatal macaques
In a separate study, eight macaque newborns were also
exposed orally to SHIV89.6P. Four control animals were left
untreated (Fig. 2A), whereas four infants were treated
intramuscularly (I.M.) with three nmAbs (2F5, 2G12, and
4E10) 24 h post-exposure and, again, 8 days later (Fig. 2B).
All four controls displayed high levels of plasma vRNA,
dropped their CD4 counts irreversibly within 2 weeks after
challenge, and died of AIDS (Figs. 2C, E). All treated
animals became viremic, but with delayed and lower peaks of
viremia than the controls. None of the infants given
immunoprophylaxis showed acute disease. In fact, differences
between CD4+ T-cell counts in control versus treated animals
were significant (pweek 5=0.03). Three of the treated animals
remained healthy throughout a follow-up of 24 weeks (Fig.
2F), whereas the nmAb-treated infant that displayed the
highest viremia set-point (ROp-9) presented with a slow
decline in CD4+ T-cell counts starting a few weeks post-
challenge (Figs. 2D, F).
Humoral immune responses
Control animals remained seronegative as assessed by
Western blot assay (Fig. 3A) and/or ELISA (data not shown),
a result that can be explained by early progression to AIDS,
Fig. 1. (A–C) Experimental design of the first neonatal immunoprophylaxis study (1 h or 12 h post-exposure immunization with 4 nmAbs). (D–I) Plasma viremia and T-helper cell counts. (A) Four newborn macaques
served as untreated controls and were given only oral virus. (B) Seven newborn macaques were challenged orally with 15 AID50 of SHIV89.6P (yielding 99% probability of infection) within 5 days of birth (open arrows)
and infused twice I.V. with human nmAbs IgG1b12, 2G12, 2F5, and 4E10 (30 mg/kg each—solid black arrows). The first mAb infusion started either 1 h or 12 h post-virus exposure; identical treatment was administered
on day 8 or 8.5 post-challenge, respectively. Animals were observed for at least 47 months. Plasma vRNA load (D–F) and peripheral absolute CD4+ T-cell counts (G–I) of neonates challenged orally with SHIV89.6P.
The sensitivity of the RT-PCR assay was 50 copies/ml (D–F), dotted line. †All control animals were sacrificed within 7 weeks post-exposure because of AIDS-related conditions; nmAb-treated infant RAq-8 was
sacrificed at week 7 for causes non-related to the virus challenge, whereas nmAb-treated macaque RYr-8 was euthanized at week 69 because of AIDS-associated clinical conditions.
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Fig. 2. (A–B) Experimental design of the second neonatal immunoprophylaxis study (24 h post-exposure prophylaxis (PEP) with 3 nmAbs). (C–F) Plasma viremia
and T-helper cell counts. (A) Four newborn macaques served as untreated controls and were challenged orally with 15 AID50 of SHIV89.6P (yielding 99% probability
of infection) within 5 days of birth (open arrows). (B) Four newborn macaques were also challenged orally with 15 AID50 of SHIV89.6P (open arrows) and then treated
twice I.M. with human nmAbs 2G12, 2F5, and 4E10 (40 mg/kg each—solid black arrows). The first mAb administration started 24 h post-virus exposure; identical
treatment was administered on day 9 post-challenge. Animals were observed for at least 8 months. Plasma vRNA load (C–D) and peripheral absolute CD4+ T-cell
counts (E–F) of neonates challenged orally with SHIV89.6P. The sensitivity of the RT-PCR assay was 50 copies/ml (C and D, dotted line). †All control animals were
sacrificed within 14 weeks post-exposure.
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humoral immune responses. In both studies, only nmAb-treated
animals that were overtly infected (sustained vRNA levels >104
copies/ml) developed anti-SIV and/or HIV antibodies, whereas
monkeys with negative plasma and cellular viremia did not
seroconvert (Fig. 3). As such, animal RWq-8, which had low-
level vRNA blips at some time points, was negative by Western
blot analysis at 58 weeks post-inoculation (Fig. 3A). The fact
that monkey ROp-9, given PEP at 24 h, had no anti-SIV Gag
reactivity at week 54 (Fig. 3A) is due to its severe depletion of
CD4 T cells, starting from week 28 onward. At this time point,
no anti-SIV Gag reactivity was seen (Fig. 3B), although theanimal had mounted anti-HIV-1 Env antibody responses (Fig.
3C). This observation is consistent with the notion that selective
loss of anti-Gag antibody responses is a poor prognostic sign
that heralds immunodeficiency (Binley et al., 1997).
Serum or plasma nAb titers were also assessed in vitro against
SHIV89.6P. Treated animals of both studies displayed early
(weeks 1–5) neutralizing activity as a direct consequence of the
passive administration of human nmAbs, whereas only animals
that were not protected from infection mounted virus-specific
neutralizing antibody (nAb) responses, which were detectable at
later time points (Table 1). The five control animals that could be
tested for the presence of nAb showed borderline- or low-
Fig. 3. Plasma anti-SIV (A and B) or anti-HIV (C) antibody assessment by Western blot for the 1 h or 12 h PEP and 24 h PEP studies. In addition to the controls
provided by the manufacturer, pre- and post-challenge plasma from animals infected with a SHIV clade C were use as negative and positive controls of the assay,
respectively.
73F. Ferrantelli et al. / Virology 358 (2007) 69–78positive titers at one or two time points post-challenge. Baseline
low titers found in several animals at time zero were likely due to
non-specific antiviral activity of individual serum/plasma
samples.
Cellular immune responses
Cellular immune responses of treated animals in the 1 h
vs. 12 h PEP study were assessed by ELISPOT assay
between weeks 29 and 33 and by proliferation assays at
different time points after virus challenge. PBMC of
monkeys that had undetectable plasma viremia at all times
(RQp-8) or low-level vRNA blips (RWq-8 and RQs-8) did
not respond to in vitro stimulation with Gag, Pol, or Nef
peptides as assessed by ELISPOT (not shown); these three
animals had also been consistently negative for proviralDNA sequences in their PBMC DNA within the limits of
our assay sensitivity. In contrast, infected, nmAb-treated
macaques RYq-8 and RPs-8 showed positive ELISPOTS to
at least two viral antigens (not shown). Conversely, animal
RYr-8, which was also virus-positive, did not display
positive ELISPOTS, consistent with its concomitant immu-
nodeficiency at the time of testing (ELISPOT analysis
performed at week 31; week 32, CD4+ T-cell counts: 17
cells/μl). All nmAb-treated animals, except for RAq-8
(which was no longer in the study after the first 7 weeks)
and RPs-8, exhibited low-positive, yet significant, viral-
antigen-specific proliferative responses to either Gag, Nef, or
Env proteins at least once or twice between weeks 12 and
40 post-challenge (SI ≥4) (Table 2). This finding can be
explained by considering that even nmAb-treated animals
that were protected from persistent systemic infection had
Table 1
Serum or plasma neutralizing antibody titers to SHIV89.6P a
Group Animal # b Outcome of virus challenge Weeks post-exposure
0 1 2 5 8 12 20 40
Control RPo-8 AIDS, death <20 51 <20 <20 <20 c nt d nt nt
1 h PEP RAq-8 Protected from infection <20 62 213 30 <20 c nt nt nt
1 h PEP RQp-8 e Protected from infection nt 118 224 <20 <20 <20 <20 <20
1 h PEP RWq-8 Transient vRNA blips; protected from disease <20 nt 147 43 nt nt nt <20 f
1 h PEP RYq-8 Protected from disease <20 228 184 85 nt 1792 nt 315
12 h PEP RPs-8 Protected from disease <20 64 194 36 50 193 nt 77 g
12 h PEP RQs-8 Transient vRNA blips; protected from disease <20 nt 310 101 <20 <20 nt <20 g
12 h PEP RYr-8 h Delayed disease <20 212 215 53 938 >540 3168 455
Control RMp-9 AIDS, death 41 nt 46 <20 <20 <20 i nt nt
Control RPp-9 AIDS, death <20 nt 28 nt 45 <20 nt nt
Control RWn-9 AIDS, death <20 nt 22 22 <20 j <20 nt nt
Control RZn-9 AIDS, death <20 nt <20 34 74 <20 k nt nt
PEP 24 h RHu-9 Protected from disease <20 105 871 59 60 41 2527 nt
PEP 24 h RIt-9 Protected from disease 20 21 352 236 827 1695 797 nt
PEP 24 h RLp-9 Protected from disease <20 139 340 50 6337 22,706 24,347 nt
PEP 24 h ROp-9 Protected from acute disease 25 104 510 176 1438 20,361 22,946 nt
a nAb titers are the reciprocal serum or plasma dilution at which 50% of cells were protected from virus-induced killing as measured by neutral red uptake. This
corresponds to a 90% reduction of the viral Gag synthesis (Bures et al., 2000).
b No data available for control animals REq-8, RFq-8, or RSl-8 because of the lack of samples.
c Sample collected at week 7.
d nt=not tested.
e RQp-8 also had titers <20 at weeks 16 and 24.
f Sample collected at week 45.
g Sample collected at week 41.
h RYr-8 also had a titer of 1515 at week 16.
i Sample collected at week 14.
j Sample collected at week 7.
k Sample collected at week 11.
74 F. Ferrantelli et al. / Virology 358 (2007) 69–78been exposed to live virus and might have therefore
mounted some antiviral cellular immune responses.
Discussion
In the first study reported here, two groups of neonatal
macaques were challenged orally with SHIV89.6P and treatedTable 2
I.V. 1 h vs. 12 h PEP: T-cell proliferative responses after SHIV89.6P challenge a
Group (PEP at) Animal # Weeks 12 We
Gag Nef Env Con A Ga
1 h PEP RQp-8 b 2 c 3 c 7 c 67 c ≤1
2
1 h PEP RWq-8 d nt e nt nt nt 8
1 h PEP RYq-8 g nt nt nt nt 3
12 h PEP RPs-8 h nt nt nt nt ≤1
12 h PEP RQs-8 i ≤1 16 3 24 ≤1
12 h PEP RYr-8 nt nt nt nt ≤1
a Proliferation stimulation indices for PBMC in the presence of soluble proteins ≥
≥4 are in bold and underlined and indicate positive responses.
b RQp-8 was tested also at weeks 36 and 44: no antigen-specific responses were
c Sample from week 16.
d RWq-8 was tested also at week 37: no antigen-specific responses were detected
e nt=not tested.
f Sample from week 41.
g RYq-8 was tested also at week 37: no antigen-specific responses were detected.
h RPs-8 was tested also at weeks 26 and 37: no antigen-specific responses were d
i RQs-8 was tested also at weeks 26 and 37: no antigen-specific responses were dI.V. with a quadruple combination of nmAbs as either 1 h or
12 h PEP, whereas the control group was exposed to oral virus
but left untreated. All four controls became highly viremic and
had to be euthanized within 7 weeks because of AIDS. In the
1 h PEP group, three out of four newborns were protected from
persistent systemic infection against SHIV89.6P challenge, and
the fourth monkey was protected from disease. When giveneks 28–33 Weeks 40
g Nef Env Con A Gag Nef Env Con A
2 ≤1 24 ≤1 ≤1 ≤1 28
2 3 58
2 2 64 ≤1 f ≤1 f ≤1 f 22 f
≤1 4 98 ≤1 f ≤1 f ≤1 f 7 f
≤1 2 34 nt nt nt nt
≤1 2 169 nt nt nt nt
≤1 9 18 ≤1 3 5 7
4 assayed at various time points after SHIV89.6P challenge. Stimulation indices
detected.
.
etected.
etected.
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out of three neonates, and disease was either prevented or
delayed in the two other infant monkeys. This study provided
the proof of concept that 12 h PEP with nmAbs given I.V. can
be protective against oral challenge with the highly pathogenic
SHIV.
These results were further extended by another study in
macaque newborns (Ferrantelli et al., 2004b), in which a triple
combination of anti-HIV nmAbs (2G12, 2F5, and 4E10) given
I.M. as 1 h PEP protected all treated infants from oral challenge
with SHIV89.6P. Taken together, these and the previous data led
to the second study reported here, in which the same triple
combination of nmAbs was administered I.M. 24 h post-virus
exposure. All four treated neonatal macaques were protected
from acute SHIV89.6P-caused disease; three of the infants have
been healthy throughout a follow-up of 8 months, whereas the
fourth animal had a decline in CD4 counts by week 20 after
virus exposure. All four control infants were infected and had
severe losses of CD4+ T cells within 2 weeks.
The present work delineates the potential and the limits of
passive immunoprophylaxis with human nmAbs. Taken
together with our results from other PEP studies (Ferrantelli
et al., 2003, 2004b), our data show that the success of pas-
sive immunization depends on the nmAb potency/dose and
the time window between virus exposure and the start of
immunoprophylaxis.
Given that PEP with human nmAbs completely prevented
systemic infection in some of the experimental animals,
potential protective mechanisms need to be considered. Clearly,
the nmAbs' direct neutralizing ability blocks virus entry, but
this mechanism alone does not explain why virus did not
reappear in the completely protected monkeys after all passively
administered human nmAbs were cleared. It is likely that,
during the initial time period when no nmAbs were present,
virions penetrated the mucosa of the oral cavity or gastro-
intestinal (GI) tract. After nmAb treatment was administered,
cell-free virus was then covered by human antibodies and
eliminated through phagocytosis of immune complexes by cells
bearing either complement or Fc-receptors, including antigen
presenting cells (reviewed byMc Cann et al., 2005). In addition,
we believe it quite likely that a few target cells were
productively infected during the time window between virus
challenge and nmAb treatment. Such cells would then be
destroyed via different, though not mutually exclusive mechan-
isms, including antibody-dependent cell-mediated cytotoxicity
(ADCC) or complement activation. Consistent with this
hypothesis, three of the human nmAbs, which share the same
IgG1 backbone, have been found previously to activate
complement and to possess ADCC activity in vitro (Hezareh
et al., 2001; Trkola et al., 1996; Wolbank et al., 2003). Lastly, it
is also possible that productive infection of early target cells
occurring before nmAb treatment led to presentation of viral
peptides on MHC class I molecules. This in turn would generate
MHC class I-restricted cytotoxic lymphocyte (CTL) responses
that could work in concert with ADCC to eliminate the virus-
producing early target cells. We did not have sufficient numbers
of cells to conduct studies to assess the generation of MHC classI-restricted cellular immune responses during the first month of
life, when such responses were most likely detectable. When we
tested for ELISPOT responses later on, the virus-exposed,
uninfected animals were negative. However, we have detected
positive, but low-level, virus-specific proliferative responses in
some of the protected infants.
It will be important to assess the longest time interval post-
virus exposure at which nmAb prophylaxis can still provide
complete protection. Such a time window might reasonably be
between 6 and 12 h post-exposure. In fact, in our 12 h PEP
study, I.V. administration of a quadruple nmAb combination
protected one of three newborns against persistent infection
after oral exposure to pathogenic SHIV89.6P. This result
suggests that both the time window post-exposure and treatment
potency in that study arm were, overall, borderline protective
against infection. It is possible that the triple combination of
2G12, 2F5, and 4E10, which was given at the higher dose of
40 mg/kg and which protected 4 out of 4 treated animals either
from infection when administered I.M. as 1 h PEP (Ferrantelli et
al., 2004b) or from disease when given as 24 h PEP, might still
provide sterilizing immunity when given within 6–12 h post-
exposure. In line with this hypothesis, a recent study showed
that antiviral neutralizing polyclonal IgG which did not protect
2 out of 2 pig-tailed macaques from infection when adminis-
tered 24 h after I.V. SHIV challenge indeed conferred sterilizing
immunity to 3 of 4 macaques when given 6 h post-virus
exposure (Nishimura et al., 2003).
It should be noted that, even though 24 h PEP with human
nmAbs was not sterilizing in our preclinical SHIV/primate
model, the same 24 h PEP regimen might still be completely
protective in a clinical setting. In fact, virus inocula associated
with natural exposure are much lower than those given to
monkeys, which correspond to 99% probability of infection
(Spouge, 1992).
Also of note, the nmAbs used in our PEP studies in neonatal
monkeys have shown potent cross-clade and cross-group
neutralizing activity in vitro against primary HIV isolates.
Several independent studies attested that such nmAbs, when
used in various combinations or even as single neutralizing
agents, neutralized most primary isolates tested and belonging
to HIV clade A, B, C, D, E, and F (Binley et al., 2004;
Kitabwalla et al., 2003; Stiegler et al., 2001; Trkola et al., 1995;
Verrier et al., 2001; Xu et al., 2001; Zwick et al., 2001a, 2001b),
or group O (Ferrantelli et al., 2004a). Moreover, among the
nmAbs that were protective in our neonatal preclinical studies,
2G12, 2F5, and 4E10 have already been proven safe and shown
to have relatively long half-lives in phase I clinical trials
involving HIV-infected human adults (Armbruster et al., 2002,
2004; Cavacini et al., 1998; Wolfe et al., 1996). The
combination of nmAbs 2G12 and 2F5 also had antiviral activity
in asymptomatic HIV-infected individuals, as evaluated in a
phase I study (Stiegler et al., 2002).
In a more recent study (Trkola et al., 2005), the triple
combination of 2G12, 2F5, and 4E10 was evaluated in adult
individuals with either acute or chronic, stable HIV-1
infection that was completely suppressed by highly active
antiviral therapy (HAART). These individuals received
76 F. Ferrantelli et al. / Virology 358 (2007) 69–78passive immunization after HAART interruption, and the
ability of the human nmAb combination to prevent or delay
virus rebound was assessed. While the nmAb treatment was
well tolerated in all individuals, efficacy was more
pronounced in the acutely infected cohort. Analysis of viral
neutralization escape mutants revealed that only nmAb 2G12
appeared to exert selective pressure. Detailed pharmacoki-
netic analysis demonstrated that this nmAb had a signifi-
cantly longer half-life and higher peak and trough levels than
the two anti-gp41 nmAbs, 2F5 and 4E10. More recently,
these same two nmAbs were reported to crossreact with
cardiolipin (Haynes et al., 2005). It is possible that this
autoreactivity may account for the more rapid elimination of
2F5 and 4E10 compared to 2G12, as all three of these
nmAbs share the same IgG1 backbone. The fourth nmAb we
used in our neonatal primate study, IgG1b12, was found to
recognize ribonucleoprotein, double-stranded DNA, and other
autoantigens (Haynes et al., 2005).
Our neonatal primate model was originally designed to
allow evaluation of strategies aimed at preventing mother-to-
child transmission of HIV-1 (MTCT), which can occur in
utero, during birth, or via breast-feeding. The problem of milk-
borne HIV-1 transmission is most prevalent in sub-Saharan
Africa, where many women continue to breast-feed either
because of lack of access to clean water, social pressure, and/or
fear of stigmatization. In these areas, even when perinatal
antiviral drug treatments are available, the treatment benefits
might be overcome by the practice of breast-feeding (Petra
Study Team, 2002). The latter is both difficult to avoid because
of economic and cultural reasons, and necessary, as a source of
maternal immunoglobulins (Ig) to guarantee immune protec-
tion against several pathogens to children (reviewed in
Brandtzaeg, 2003). Since intrapartum MTCT is thought to
occur predominantly via mucosal exposure of the fetus, we feel
that our oral virus challenge model in neonatal monkeys
mimics important aspects of intrapartum MTCT, in addition to
serving as a model for milk-borne virus transmission. We have
used this model to develop passive immunization with
combinations of broadly reactive human nmAbs to prevent
MTCT via breast feeding. At the same time, passive
immunization given soon after delivery may serve as PEP
after intrapartum virus exposure. If successful as a true
prophylactic regimen and if a sufficiently large time window
between virus exposure and onset of nmAb therapy can be
demonstrated, passive immunization with broadly reactive
human nmAbs may be clinically beneficial as PEP after
intrapartum HIV-1 exposure and as prevention of milk-borne
HIV-1 transmission.
Given the sobering data by Haynes et al. (2005) that the
majority of the human nmAbs we used in our neonatal primate
studies exhibit anti-self reactivity, we believe that such
autoreactivity may potentially complicate the use of the
human nmAbs in passive immunization. In the future, it will
be important to perform more extensive safety studies with the
currently available broadly reactive human nmAbs, especially
with 4E10, which has been reported to possess lupus
anticoagulant activity (Haynes et al., 2005). Equally importantwill be the identification of new, potent nmAbs with broad
antiviral reactivity but hopefully lacking autoreactivity. This
approach could lead to the identification of novel, conserved
epitopes that could have a significant impact on the
development of nAb-responses-based AIDS vaccines. Overall,
passive immunization with human nmAbs in the SHIV/
nonhuman primate models is a very useful tool to assess the
importance of Abs against HIV infection.
Materials and methods
Animals, SHIV89.6P challenge and human nmAb
administration
Rhesus macaques were housed at the Yerkes National
Primate Research Center, Emory University, a facility fully
accredited by the Association for Assessment and Accredita-
tion of Laboratory Animal Care International. All procedures
were approved by the Animal Care and Use Committees of
Emory University and the Dana-Farber Cancer Institute. We
are committed to comply with the Principles for Use of
Animals, the Guide for the Care and Use of Laboratory
Animals, the Provisions of the Animal Welfare Act, and other
applicable laws and regulations.
The SHIV89.6P stock was prepared and titrated as
described previously (Hofmann-Lehmann et al., 2001). Within
5 days of birth, newborn macaques were challenged orally
with fifteen 50% animal infectious doses (AID50) as reported
previously (Ferrantelli et al., 2003).
Either triple or quadruple combinations of human IgG1
nmAbs 2G12, 2F5, 4E10, and IgG1b12 were used in these
studies. 2G12 recognizes a conformational epitope consisting
of mannose residues on the gp120 subunit of HIV Env
(Scanlan et al., 2002); 2F5 and 4E10 bind the conserved HIV
gp41 sequences ELDKWA (Muster et al., 1993; Parker et al.,
2001) and NWFDIT (Stiegler et al., 2001; Zwick et al., 2001a),
respectively. 2G12, 2F5, and 4E10 were provided by Polymun
Scientific, Vienna, Austria. IgG1b12 targets the CD4 binding
site of gp120 (Roben et al., 1994) and was produced as
described (Hofmann-Lehmann et al., 2001). nmAbs were of
clinical grade purity and endotoxin-free.
The first part of the present study included 11 neonatal rhesus
monkeys, all of which were exposed orally to the pathogenic
SHIV89.6P. One control group of 4 animals was left untreated,
whereas a group of 4 newborn macaques was infused I.V. with
human nmAbs IgG1b12, 2G12, 2F5, and 4E10 (30 mg/kg of
body weight for each antibody) 1 h post-inoculation. Another
treatment group of 3 neonates received the four nmAbs starting
at 12 h post-challenge. The identical nmAb regimen was given to
all 7 treated infants on day 8 post-inoculation. nmAbs were
administered I.V. through a 0.2 μm syringe filter previously
flushed with physiological solution. In the second experiment, 8
newborn macaques were challenged orally with SHIV89.P. Four
animals were left untreated as controls, whereas the other 4
neonates were treated twice I.M. with the three human nmAbs
2G12, 2F5, and 4E10 at a dose of 40mg/kg each, 24 h and 9 days
post-challenge.
77F. Ferrantelli et al. / Virology 358 (2007) 69–78Cocultivation of PBMC, measurement of plasma vRNA and
cellular viral DNA levels
PBMC were co-cultured with CEM×174/GFP cells as
described previously (Rasmussen et al., 2002). Plasma vRNA
loads were assessed by quantitative RT-PCR for SIV gag
sequences (QiaAmp RNA Blood Mini-Kit—Qiagen) (Hof-
mann-Lehmann et al., 2000), and the presence of viral DNAwas
similarly evaluated in PBMC by PCR for SIV gag sequences.
Lymph node cell sample preparation and vRNA/DNA detection
Lymph node cells were isolated from 1 to 2 inguinal lymph
nodes per animal by enzymatic digestion to ensure the pre-
servation of follicular dendritic cells amid other cell types, as
reported (Ferrantelli et al., 2004b). Cell samples were therefore
assayed by RT-PCR (QiaAmp RNA Blood Mini-Kit—Qiagen)
for SIV-RNA gag sequences or SIV gag DNA (sensitivity, 1
copy of viral DNA per μg of genomic DNA) (Hofmann-
Lehmann et al., 2000).
Serological assays
Triplicate plasma samples were tested for the presence of
anti-SIV or anti-HIV antibodies by Western blot assay
(ZeptoMetrix) according to the manufacturer's instructions
and/or by ELISA using recombinant SIV p27 (Baba et al.,
2000). Serum or plasma nAb titers against a SHIV89.6P
produced in human PBMC were measured by an MT-2 cell-
based killing assay (Bures et al., 2000; Crawford et al.,
1999).
Cellular immunity
PBMC were tested in triplicate wells for antigen-specific
proliferative responses against SIVmac239 Gag, Nef (AIDS
Research Reference Reagent Program, NIAID, NIH), or
HIV89.6 Env (kindly provided by P. Earl, NIAID, NIH) as
described (Rasmussen et al., 2002); stimulation indices (SI)
were calculated as reported previously (Ferrantelli et al.,
2004b) and considered positive when ≥4. ELISPOT assays
were also performed as described (Larsson et al., 1999).
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